Rocket Pharmaceuticals, Inc. RCKT
We take great care to ensure that the data presented and summarized in this overview for ROCKET PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RCKT
View all-
Rtw Investments, LP New York, NY17.7MShares$59.1 Million1.93% of portfolio
-
Wellington Management Group LLP Boston, MA12.6MShares$42.2 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.62MShares$22.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$20.7 Million0.0% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx5.2MShares$17.4 Million0.68% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.82MShares$16.1 Million0.17% of portfolio
-
State Street Corp Boston, MA3.71MShares$12.4 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.5MShares$11.7 Million1.02% of portfolio
-
Janus Henderson Group PLC London, X03.29MShares$11 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.04MShares$10.2 Million0.0% of portfolio
Latest Institutional Activity in RCKT
Top Purchases
Top Sells
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Insider Transactions at RCKT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 03
2025
|
Aaron Ondrey Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,477
-1.14%
|
$2,954
$2.88 P/Share
|
Jun 18
2025
|
David P Southwell |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+48.65%
|
-
|
Jun 18
2025
|
Elisabeth Bjork |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
Jun 18
2025
|
Carsten Boess |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
Jun 18
2025
|
Fady Ibraham Malik |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
Jun 18
2025
|
Roderick Wong |
BUY
Grant, award, or other acquisition
|
Direct |
47,667
+38.52%
|
-
|
Jun 18
2025
|
Gotham Makker |
BUY
Grant, award, or other acquisition
|
Indirect |
49,434
+5.76%
|
-
|
Jun 18
2025
|
Mikael Dolsten |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+40.42%
|
-
|
Jun 18
2025
|
Pedro P Granadillo |
BUY
Grant, award, or other acquisition
|
Direct |
54,734
+40.56%
|
-
|
Jun 18
2025
|
Piratip Pratumsuwan |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
May 20
2025
|
Martin Wilson General Counsel |
SELL
Open market or private sale
|
Direct |
587
-0.39%
|
$3,522
$6.45 P/Share
|
May 20
2025
|
Gaurav Shah CEO |
SELL
Open market or private sale
|
Direct |
2,253
-0.29%
|
$13,518
$6.45 P/Share
|
May 20
2025
|
Kinnari Patel |
SELL
Open market or private sale
|
Direct |
767
-0.17%
|
$4,602
$6.45 P/Share
|
May 20
2025
|
Jonathan David Schwartz |
SELL
Open market or private sale
|
Direct |
801
-0.34%
|
$4,806
$6.45 P/Share
|
May 20
2025
|
John Militello |
SELL
Open market or private sale
|
Direct |
357
-0.55%
|
$2,142
$6.45 P/Share
|
May 16
2025
|
Martin Wilson General Counsel |
SELL
Open market or private sale
|
Direct |
946
-0.63%
|
$5,676
$6.53 P/Share
|
May 16
2025
|
Gaurav Shah CEO |
SELL
Open market or private sale
|
Direct |
3,621
-0.46%
|
$21,726
$6.53 P/Share
|
May 16
2025
|
Jonathan David Schwartz |
SELL
Open market or private sale
|
Direct |
1,582
-0.67%
|
$9,492
$6.53 P/Share
|
May 16
2025
|
Kinnari Patel |
SELL
Open market or private sale
|
Direct |
1,409
-0.32%
|
$8,454
$6.53 P/Share
|
May 16
2025
|
John Militello |
SELL
Open market or private sale
|
Direct |
655
-1.01%
|
$3,930
$6.53 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 752K shares |
---|---|
Other acquisition or disposition | 14.2K shares |
Open market or private purchase | 41.1K shares |
Open market or private sale | 103K shares |
---|